Key Takeaways
- Sector: Biotechnology & Life Sciences.
- Geography: Switzerland, United States.
Analysis
Siegfried Holding AG has struck a deal to acquire the manufacturing and extraction arms of the Noramco Group from affiliates of funds advised by SK Capital, marking another consolidation step in the global CDMO and API supply chain. The agreement covers the businesses operating as Noramco, Extractas Biosciences and Purisys, while SK Capital will continue to own Halo Pharmaceuticals.
The transaction deepens Siegfried’s footprint in active pharmaceutical ingredients (APIs) and contract development and manufacturing services. Siegfried reported sales of CHF 1.295 billion in 2024 and operates more than 3,800 employees across multiple sites—assets that the company can now integrate with the Noramco Group’s North American API and plant-extraction capabilities.
For SK Capital, a sector-focused private investment firm with roughly $10 billion in assets under management as disclosed by the firm, the divestiture allows management to concentrate on scaling Halo Pharmaceuticals as a standalone sterile-fill-finish and controlled-substance CDMO in the US and Canada. Aaron Davenport, Managing Director at SK Capital and Chairman of Noramco’s board, said the firm will continue to back Halo as it pursues targeted growth.
Advisory teams on the deal included Jefferies acting as lead financial adviser, alongside RBC Capital Markets, LLC and Rothschild & Co. The sale remains subject to customary closing conditions and regulatory approvals in relevant jurisdictions.
Strategically, the move reflects two concurrent trends in pharma manufacturing: greater vertical integration among CDMOs aiming to secure API supply and ongoing consolidation as buyers seek scale, geographic breadth and regulatory resilience. The global CDMO market is widely estimated in the low hundreds of billions of dollars with steady mid-single to high-single-digit CAGR, making scale and specialized capabilities increasingly valuable.
Market implications are practical. For Siegfried, the addition of Extractas’ plant-extraction know-how and Purisys’ clinical API capabilities could accelerate development-to-commercial supply chains for controlled substances and complex alkaloid-derived APIs. For SK Capital, freeing management bandwidth and capital to grow Halo allows a concentrated push into finished-dose manufacturing, where demand for sterile and controlled-substance capacity remains tight.
Execution risks include regulatory clearances, integration of technical processes and the often-complex handling of controlled substances across jurisdictions. Nonetheless, the deal underscores a broader strategic reallocation of assets in the life-sciences manufacturing landscape and points to further M&A activity among CDMOs and API suppliers over the coming quarters.